Live from the NIH registry
Studies recruiting near Detroit right now
Top 25 of 1,189 recruiting studies, sorted by proximity — each links to its official registry page
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Henry Ford Health Saint John Hospital — Detroit, Michigan (4.6 mi)
· Sponsor: American Society of Clinical Oncology
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Age-Related Macular Degeneration, Geographic Atrophy
N/A
Interventional 125 participants sought
Oakland Ophthalmic Surgery — Birmingham, Michigan (12.6 mi)
· Sponsor: VisionCare, Inc.
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Large Cell Lymphoma, Diffuse, Relapsed Cancer
Phase 2
Interventional 35 participants sought
Karmanos Cancer Center (Wayne State University) — Detroit, Michigan (4.6 mi)
· Sponsor: Dipenkumar Modi
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Children's Hospital of Michigan — Detroit, Michigan (4.6 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Phase 2
Interventional 120 participants sought
Karmanos Cancer Institute — Detroit, Michigan (4.6 mi)
· Sponsor: Regeneron Pharmaceuticals
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
St. Clair Nephrology Research — Shelby, Michigan (20.2 mi)
· Sponsor: R1 Therapeutics
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Profound Research LLC — Royal Oak, Michigan (7.6 mi)
· Sponsor: Relay Therapeutics, Inc.
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Phase 2
Interventional 40 participants sought
Wayne State University Physician Group Dermatology — Detroit, Michigan (4.6 mi)
· Sponsor: Incyte Corporation
A Study of the TheraBionic P1 Device in Breast Cancer
Breast Cancer Stage I, Breast Cancer Stage II
N/A
Interventional 24 participants sought
Karmanos Cancer Institute — Detroit, Michigan (4.6 mi)
· Sponsor: Barbara Ann Karmanos Cancer Institute
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Hypertension, Pulmonary, Lung Diseases, Interstitial
Phase 2
Interventional 25 participants sought
Allen Park — Allen Park, Michigan (10.3 mi)
· Sponsor: Tectonic Operating Company, Inc.
Nonopioid Analgesia After Labral Surgery
Narcotic Use
Phase 2, Phase 3
Interventional 100 participants sought
Henry Ford Health System — Detroit, Michigan (4.6 mi)
· Sponsor: Henry Ford Health System
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Wayne State University/Karmanos Cancer Institute — Detroit, Michigan (4.6 mi)
· Sponsor: SWOG Cancer Research Network
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
N/A
Interventional 500 participants sought
Henry Ford Hospital — Detroit, Michigan (4.6 mi)
· Sponsor: EnCompass Technologies, Inc.
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Detroit, Michigan (4.6 mi)
· Sponsor: AstraZeneca
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Phase 3
Interventional 1,300 participants sought
Wayne State University School of Medicine — Detroit, Michigan (4.6 mi)
· Sponsor: Kura Oncology, Inc.
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Karmanos Cancer Institute — Detroit, Michigan (4.6 mi)
· Sponsor: Eli Lilly and Company
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Phase 2
Interventional 90 participants sought
Wayne State University — Detroit, Michigan (4.6 mi)
· Sponsor: Takeda
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Phase 2
Interventional 100 participants sought
Karmanos Cancer Institute — Detroit, Michigan (4.6 mi)
· Sponsor: C4 Therapeutics, Inc.
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Narcolepsy
Phase 2
Interventional 64 participants sought
Revive Research Institute - Southfield - 23999 Northwestern Hwy — Southfield, Michigan (8.7 mi)
· Sponsor: Eisai Inc.
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection Recurrence
Phase 2
Interventional 20 participants sought
Henry Ford Hospital — Detroit, Michigan (4.6 mi)
· Sponsor: Acurx Pharmaceuticals Inc.
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Spasticity
Phase 1, Phase 2
Interventional 240 participants sought
Quest Research Institute — Farmington Hills, Michigan (15.7 mi)
· Sponsor: Ipsen
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Associated Retinal Consultants PC — Royal Oak, Michigan (7.6 mi)
· Sponsor: Genentech, Inc.
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Phase 2, Phase 3
Interventional 455 participants sought
Karmanos Cancer Center — Detroit, Michigan (4.6 mi)
· Sponsor: Oncotelic Inc.
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Phase 2
Interventional 200 participants sought
Wayne State University — Detroit, Michigan (4.6 mi)
· Sponsor: Novartis Pharmaceuticals
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Detroit, Michigan (4.6 mi)
· Sponsor: Sameek Roychowdhury